Nyxoah (NASDAQ:NYXH) Given “Overweight” Rating at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Nyxoah (NASDAQ:NYXH) in a report released on Monday,Benzinga reports. They currently have a $11.00 price target on the stock.

NYXH has been the topic of a number of other reports. Stifel Nicolaus dropped their target price on Nyxoah from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Nyxoah in a report on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Nyxoah currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.25.

Nyxoah Trading Up 2.6%

NYXH opened at $3.16 on Monday. The firm’s 50 day moving average is $4.29 and its 200-day moving average is $4.81. Nyxoah has a 52-week low of $3.02 and a 52-week high of $11.87. The company has a quick ratio of 1.16, a current ratio of 1.25 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $122.48 million, a P/E ratio of -1.18 and a beta of 1.56.

Nyxoah (NASDAQ:NYXH) last announced its earnings results on Thursday, March 19th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.03). The firm had revenue of $6.62 million during the quarter, compared to analysts’ expectations of $5.70 million. Nyxoah had a negative net margin of 884.69% and a negative return on equity of 139.18%. Analysts expect that Nyxoah will post -1.91 EPS for the current fiscal year.

Hedge Funds Weigh In On Nyxoah

A number of hedge funds have recently bought and sold shares of the company. Franklin Resources Inc. grew its position in shares of Nyxoah by 0.9% in the 2nd quarter. Franklin Resources Inc. now owns 294,990 shares of the company’s stock worth $2,207,000 after acquiring an additional 2,655 shares in the last quarter. Bank of America Corp DE raised its position in shares of Nyxoah by 72.4% during the 2nd quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock valued at $59,000 after acquiring an additional 3,303 shares in the last quarter. Raymond James Financial Inc. raised its position in shares of Nyxoah by 35.6% during the 3rd quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock valued at $59,000 after acquiring an additional 3,353 shares in the last quarter. Deutsche Bank AG lifted its stake in Nyxoah by 40.0% during the fourth quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock worth $161,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Rossmore Private Capital lifted its stake in Nyxoah by 12.6% during the third quarter. Rossmore Private Capital now owns 132,746 shares of the company’s stock worth $616,000 after purchasing an additional 14,806 shares during the last quarter.

About Nyxoah

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.